# Alteogen Secures $149M Investment

> Korean biotech Alteogen lands $149M convertible funding from state-backed investors to expand manufacturing and license drug technologies.
- Title: Alteogen Secures $149M Investment · Dealroom | Shortify
- Summary: Korean biotech Alteogen lands $149M convertible funding from state-backed investors to expand manufacturing and license drug technologies. Alteogen secured…
- Keywords: alteogen, national growth fund, skylake equity partners, convertible funding, biotech, drug licensing, manufacturing expansion, startups, business, Secures, 149M, Investment
- Source: Dealroom — https://dealroom.co/news/160205-alteogen-lands-149m-convertible-from-korean-growth-fund-skylake
- Published: 2026-10-06T09:30:33+00:00
- Read time: 1 min
- Topics: alteogen, national growth fund, skylake equity partners, convertible funding, biotech, drug licensing, manufacturing expansion, startups, business
## Alteogen Raises $167.7M
Alteogen secured $167.7 million through a post-IPO convertible issuance backed by South Korea's National Growth Fund and Skylake Equity Partners.
## Investment Structure
The round splits into $83.8 million of convertible preferred stock and $83.8 million of redeemable convertible preferred stock.
## Global Drug Licensing
Alteogen's ALT-B4 platform licenses drugs with 10 global companies including MSD, AstraZeneca, Sanofi, Novartis, and GSK.
## Key takeaway

Alteogen secured $149M from South Korea's National Growth Fund and Skylake Equity Partners to build facilities and acquire drug tech for global licensing deals.